Switch theme
Sign up to access all valuation multiples
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
62.6K+
LTM Revenue $24.0B
LTM EBITDA $6.9B
$64.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Merck KGaA has a last 12-month revenue (LTM) of $24.0B and a last 12-month EBITDA of $6.9B.
In the most recent fiscal year, Merck KGaA achieved revenue of $23.8B and an EBITDA of $6.7B.
Merck KGaA expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Merck KGaA valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $24.0B | XXX | $23.8B | XXX | XXX | XXX |
| Gross Profit | $14.2B | XXX | $14.0B | XXX | XXX | XXX |
| Gross Margin | 59% | XXX | 59% | XXX | XXX | XXX |
| EBITDA | $6.9B | XXX | $6.7B | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 28% | XXX | XXX | XXX |
| EBIT | $4.6B | XXX | $4.5B | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | 19% | XXX | XXX | XXX |
| Net Profit | $4.2B | XXX | $3.1B | XXX | XXX | XXX |
| Net Margin | 18% | XXX | 13% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $8.3B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Merck KGaA's stock price is EUR 115 (or $129).
Merck KGaA has current market cap of EUR 50.1B (or $56.3B), and EV of EUR 57.2B (or $64.2B).
See Merck KGaA trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $64.2B | $56.3B | XXX | XXX | XXX | XXX | $9.76 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Merck KGaA has market cap of $56.3B and EV of $64.2B.
Merck KGaA's trades at 2.7x EV/Revenue multiple, and 9.6x EV/EBITDA.
Equity research analysts estimate Merck KGaA's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Merck KGaA has a P/E ratio of 13.3x.
See valuation multiples for Merck KGaA and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $56.3B | XXX | $56.3B | XXX | XXX | XXX |
| EV (current) | $64.2B | XXX | $64.2B | XXX | XXX | XXX |
| EV/Revenue | 2.7x | XXX | 2.7x | XXX | XXX | XXX |
| EV/EBITDA | 9.4x | XXX | 9.6x | XXX | XXX | XXX |
| EV/EBIT | 14.0x | XXX | 14.2x | XXX | XXX | XXX |
| EV/Gross Profit | 4.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 13.3x | XXX | 18.0x | XXX | XXX | XXX |
| EV/FCF | 21.1x | XXX | 23.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMerck KGaA's last 12 month revenue growth is 3%
Merck KGaA's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Merck KGaA's rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Merck KGaA's rule of X is 36% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Merck KGaA and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | 4% | XXX | XXX | XXX |
| Rule of 40 | 30% | XXX | 31% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 36% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Merck KGaA acquired XXX companies to date.
Last acquisition by Merck KGaA was XXXXXXXX, XXXXX XXXXX XXXXXX . Merck KGaA acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| Where is Merck KGaA headquartered? | Merck KGaA is headquartered in Germany. |
| How many employees does Merck KGaA have? | As of today, Merck KGaA has 62.6K+ employees. |
| Is Merck KGaA publicy listed? | Yes, Merck KGaA is a public company listed on ETR. |
| What is the stock symbol of Merck KGaA? | Merck KGaA trades under MRK ticker. |
| When did Merck KGaA go public? | Merck KGaA went public in 1995. |
| Who are competitors of Merck KGaA? | Similar companies to Merck KGaA include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Merck KGaA? | Merck KGaA's current market cap is $56.3B |
| What is the current revenue of Merck KGaA? | Merck KGaA's last 12 months revenue is $24.0B. |
| What is the current revenue growth of Merck KGaA? | Merck KGaA revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Merck KGaA? | Current revenue multiple of Merck KGaA is 2.7x. |
| Is Merck KGaA profitable? | Yes, Merck KGaA is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Merck KGaA? | Merck KGaA's last 12 months EBITDA is $6.9B. |
| What is Merck KGaA's EBITDA margin? | Merck KGaA's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Merck KGaA? | Current EBITDA multiple of Merck KGaA is 9.4x. |
| What is the current FCF of Merck KGaA? | Merck KGaA's last 12 months FCF is $3.0B. |
| What is Merck KGaA's FCF margin? | Merck KGaA's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of Merck KGaA? | Current FCF multiple of Merck KGaA is 21.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
